British Biotech signs MMPI deal with Schering-Plough
Executive Summary
British Biotech and Schering-Plough will develop and market, as a cancer treatment, BB's matrix metalloproteinase inhibitors (MMPIs), including Marimastat and BB-3644. Schering gets exclusive worldwide rights except in Japan and those Far Eastern countries where Tanabe Seiyaku has rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice